Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 6/1997

01-06-1997 | Original Research Article

Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkin’s Lymphoma

Authors: George Dranitsaris, Christopher Altmayer, Ian Quirt

Published in: PharmacoEconomics | Issue 6/1997

Login to get access
Metadata
Title
Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkin’s Lymphoma
Authors
George Dranitsaris
Christopher Altmayer
Ian Quirt
Publication date
01-06-1997
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/1997
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-199711060-00005

Other articles of this Issue 6/1997

PharmacoEconomics 6/1997 Go to the issue

Correspondence

Cost Effectiveness and Allocation of Therapies in a Treating Population

Correspondence

Pre-Hospital Thrombolysis: The Author’s Reply

Review Article

Cost Effectiveness of Smoking-Cessation Therapies

Original Research Article

Some Aspects of the Cost of Schizophrenia in France

Erratum

Erratum to Will Managed Care Work in Europe?

Original Research Article

A Pharmacoeconomic Analysis of Patients with Symptoms of Benign Prostatic Hyperplasia